These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

751 related items for PubMed ID: 18781479

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Recent epidemiological evidence relevant to the clinical management of the menopause.
    Shapiro S.
    Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
    [Abstract] [Full Text] [Related]

  • 4. Combined hormonal contraception and venous thromboembolism.
    Martínez F, Avecilla A.
    Eur J Contracept Reprod Health Care; 2007 Jun; 12(2):97-106. PubMed ID: 17559006
    [Abstract] [Full Text] [Related]

  • 5. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
    Odlind V, Milsom I, Persson I, Victor A.
    Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300
    [Abstract] [Full Text] [Related]

  • 6. Thrombotic risks of oral contraceptives.
    Rott H.
    Curr Opin Obstet Gynecol; 2012 Aug; 24(4):235-40. PubMed ID: 22729096
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Contraception; 1998 May; 57(5):315-24. PubMed ID: 9673838
    [Abstract] [Full Text] [Related]

  • 8. Oral contraceptives, hormone replacement therapy and thrombosis.
    Rosendaal FR, Helmerhorst FM, Vandenbroucke JP.
    Thromb Haemost; 2001 Jul; 86(1):112-23. PubMed ID: 11486996
    [Abstract] [Full Text] [Related]

  • 9. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N, Smith KP.
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies.
    Shapiro S.
    Climacteric; 2006 Dec; 9(6):416-20. PubMed ID: 17085373
    [Abstract] [Full Text] [Related]

  • 13. Oral contraceptives and venous thromboembolism: consensus conference statement.
    Dialogues in Contraception Consensus Conference (1995: Chicago).
    Dialogues Contracept; 1996 Dec; ():1-8. PubMed ID: 12320455
    [Abstract] [Full Text] [Related]

  • 14. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy.
    Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF.
    Arch Intern Med; 1997 Jul 28; 157(14):1522-30. PubMed ID: 9236553
    [Abstract] [Full Text] [Related]

  • 15. Hormonal contraception and venous thromboembolism.
    Lidegaard Ø, Milsom I, Geirsson RT, Skjeldestad FE.
    Acta Obstet Gynecol Scand; 2012 Jul 28; 91(7):769-78. PubMed ID: 22568831
    [Abstract] [Full Text] [Related]

  • 16. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users.
    Samuelsson E, Hägg S.
    Acta Obstet Gynecol Scand; 2004 Jul 28; 83(7):674-81. PubMed ID: 15225194
    [Abstract] [Full Text] [Related]

  • 17. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
    Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY, Estrogen and Thromboembolism Risk (ESTHER) Study Group.
    Circulation; 2005 Nov 29; 112(22):3495-500. PubMed ID: 16301339
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular risk of oral contraceptives. Low, and mainly in women at risk.
    Prescrire Int; 1998 Aug 29; 7(36):118-24. PubMed ID: 10342951
    [Abstract] [Full Text] [Related]

  • 19. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study.
    van Vlijmen EF, Brouwer JL, Veeger NJ, Eskes TK, de Graeff PA, van der Meer J.
    Arch Intern Med; 2007 Feb 12; 167(3):282-9. PubMed ID: 17296885
    [Abstract] [Full Text] [Related]

  • 20. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
    Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP.
    Contraception; 2004 Jul 12; 70(1):3-10. PubMed ID: 15208046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.